Last week, the Food and Drug Administration announced that monoclonal antibody bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. Data from the Centers for Disease Control and Prevention published recently estimates that the combined proportion of COVID-19 cases caused by the Omicron BQ.1 and BQ.1.1 subvariants to be above 57 percent nationally, and already above 50 percent in all individual regions but one, and data shows a sustained trend of increasing prevalence across all regions. Find out more here.
NCPA
